![GSK and Moderna slide on RSV vaccine CDC updates](https://i-invdn-com.investing.com/news/LYNXMPECAK0EC_S.jpg)
Please try another search
Period Ending: | 2024 31/03 |
2023 31/12 |
2023 30/09 |
2023 30/06 |
||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 93.93 | 71.13 | 105.3 | 124.18 | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
Cost of Revenue, Total | 79.8 | 79.64 | 114.93 | 64.79 | ||||||||||||||||||||||||||||||
Gross Profit | 14.12 | -8.51 | -9.63 | 59.39 | ||||||||||||||||||||||||||||||
Total Operating Expenses | 94.69 | -39.67 | 113.76 | 121.92 | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
Operating Income | -0.764 | 110.8 | -8.47 | 2.25 | ||||||||||||||||||||||||||||||
Interest Income (Expense), Net Non-Operating | - | - | - | - | ||||||||||||||||||||||||||||||
Gain (Loss) on Sale of Assets | - | - | - | 1.83 | ||||||||||||||||||||||||||||||
Other, Net | -3.49 | 9.47 | 10.17 | 14.74 | ||||||||||||||||||||||||||||||
Net Income Before Taxes | 2.72 | 101.32 | -18.63 | -14.32 | ||||||||||||||||||||||||||||||
Provision for Income Taxes | 2.29 | 2.06 | 2.42 | 22.05 | ||||||||||||||||||||||||||||||
Net Income After Taxes | 0.438 | 99.26 | -21.05 | -36.37 | ||||||||||||||||||||||||||||||
Minority Interest | -4.58 | 0.746 | -20.61 | -18.99 | ||||||||||||||||||||||||||||||
Equity In Affiliates | - | - | - | - | ||||||||||||||||||||||||||||||
U.S GAAP Adjustment | - | - | - | - | ||||||||||||||||||||||||||||||
Net Income Before Extraordinary Items | 5.76 | 99.2 | -19.98 | -25.48 | ||||||||||||||||||||||||||||||
Total Extraordinary Items | - | - | - | - | ||||||||||||||||||||||||||||||
Net Income | 5.76 | 99.2 | -19.98 | -25.48 | ||||||||||||||||||||||||||||||
Total Adjustments to Net Income | - | - | - | - | ||||||||||||||||||||||||||||||
Income Available to Common Excluding Extraordinary Items | 5.76 | 99.2 | -19.98 | -25.48 | ||||||||||||||||||||||||||||||
Dilution Adjustment | - | - | - | -0.004 | ||||||||||||||||||||||||||||||
Diluted Net Income | 5.76 | 99.2 | -19.98 | -25.48 | ||||||||||||||||||||||||||||||
Diluted Weighted Average Shares | 657.74 | 657.74 | 598.1 | 589.1 | ||||||||||||||||||||||||||||||
Diluted EPS Excluding Extraordinary Items | 0.009 | 0.151 | -0.033 | -0.043 | ||||||||||||||||||||||||||||||
DPS - Common Stock Primary Issue | - | - | - | - | ||||||||||||||||||||||||||||||
Diluted Normalized EPS | 0.011 | 0.096 | -0.018 | 0.002 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review